GlassScriptPhysician profile
Scott M Weaner
NPI 1922084219
$6,756.43
in general payments reported to CMS, 2019-2025
37 companies · $1,548 in 2025
The $1,548 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,164 · 2020: $575 · 2021: $751 · 2022: $949 · 2023: $846 · 2024: $924 · 2025: $1,548.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,318.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,317.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,344.14 | 2021-2025 | Ubrelvy, Qulipta |
| Biogen, INC. | $795.66 | 2019-2025 | Vumerity, Tysabri, Tysabri |
| Teva Pharmaceuticals USA, INC. | $633.23 | 2019-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Amgen INC. | $523.04 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $447.91 | 2022-2025 | Zeposia |
| Axsome Therapeutics, INC. | $373.04 | 2025 | Symbravo, Auvelity |
| Ucb, INC. | $368.73 | 2019-2025 | Fintepla, Briviact |
| Lilly USA, LLC | $251.10 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Avanir Pharmaceuticals, INC. | $248.52 | 2019 | |
| Alexion Pharmaceuticals, INC. | $196.18 | 2019-2024 | Ultomiris |
| Sk Life Science, INC. | $184.79 | 2023-2024 | Xcopri |
| Lundbeck LLC | $171.08 | 2022-2024 | Vyepti |
| Novartis Pharmaceuticals Corporation | $129.30 | 2019 | |
| Allergan, INC. | $124.98 | 2020 | |
| Celgene Corporation | $116.59 | 2021-2024 | Zeposia |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $112.36 | 2023-2025 | Crexont, Rytary, Ongentys |
| Kyowa Kirin, INC. | $97.50 | 2019 | |
| Emd Serono, INC. | $85.86 | 2019-2022 | |
| Pfizer INC. | $74.04 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $52.44 | 2021-2023 | Ponvory |
| Neurocrine Biosciences, INC. | $51.96 | 2020-2023 | Ingrezza, Ongentys |
| Tanabe Pharma America, INC. | $42.42 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $42.41 | 2019-2020 | |
| Neurelis, INC. | $41.96 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $39.78 | 2021 | |
| Eisai INC. | $35.95 | 2023-2025 | |
| Acadia Pharmaceuticals INC | $26.86 | 2019 | |
| Arbor Pharmaceuticals, INC. | $20.73 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $16.59 | 2022 | |
| Azurity Pharmaceuticals, INC. | $15.88 | 2025 | Horizant |
| Argenx US, INC. | $14.91 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $13.68 | 2024 | Rexulti |
| Genentech USA, INC. | $13.65 | 2019 | |
| Upsher-Smith Laboratories LLC | $13.42 | 2020 | |
| Currax Pharmaceuticals LLC | $13.31 | 2023 | Onzetra Xsail |
| Almatica Pharma LLC | $12.08 | 2021 | |
| Corium, LLC | $10.35 | 2023 | Adlarity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Weaner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.